While the patient with breast cancer giving rise to CTC‐ITB‐01 progressed on endocrine and later chemotherapy, the added benefit of novel cyclin‐dependent kinase (CDK) 4/6 inhibitors has only recently been described for ER+ breast cancer patients (Finn et al, 2015, 2016). The gene discussed is ESR1; the disease is breast carcinoma.